US FDA approves Mirum's drug for rare bone disorder
PUBLISHED Sep 25, 2026, 4:11 PM ET
Read, Watch or Listen
The United States Food and Drug Administration has approved Mirum Pharmaceuticals' drug zilurgisertib, marketed under the brand name Atebrioz, to treat fibrodysplasia ossificans progressiva in patients aged twelve years and older. Announced on Friday, the once-daily oral medication is designed to treat the rare genetic disorder that causes bone to form abnormally within muscles, tendons, and ligaments, severely restricting patient movement and leading to permanent physical disability. Atebrioz functions by blocking ALK2, a protein that is abnormally active in most patients diagnosed with the condition and acts as the primary driver of extra-skeletal bone formation. The recommended patient dosage is one hundred milligrams daily. Mirum Pharmaceuticals chief executive officer Chris Peetz stated that the company expects to commercially launch the therapeutic product in October and plans to announce official pricing details at that time, expanding treatment access for this ultra-rare patient population nationwide.
By Haya | JQJO News
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Mirum gets FDA approval for rare bone disorder drug
Investing.com Endpoints News Stocktwits GuruFocus Drugs.com KFGO Mirum Pharmaceuticals Investor Relations Reuters Zacks Investment Research MarketWatch Bloomberg Fierce Pharma BioWorld MassDevice Managed Healthcare Executive FirstWord Pharma Specialty Pharma Journal HCP Live AJMC Healio Business Wire GlobeNewswire Morningstar Seeking Alpha Benzinga The Wall Street Journal Financial Times Marketwatch Marketplace AP News USA Today Forbes Chicago Tribune San Francisco Chronicle Houston Chronicle Seattle Times Miami Herald Dallas Morning News Phoenix Business Journal San Diego Business Journal MedPage Today Psychiatric Times The Lancet Digital Health New England Journal of Medicine Catalyst Verywell Health BioCenturyFrom Right
No right-leaning sources found for this story.
Comments